Chime Biologics Secures US$190M Series A+ Financing

27 Mar, 2021

Chime Biologics Secures US$190M Series A+ Financing
Photo by Firmbee.com on Unsplash

– Chime Biologics secures US$190m in Series A+ financing.
– The round was led by VMS Group, followed by Fidelity International and Panacea Venture.
– Chime Biologics has built a GE KuBio modular bio-manufacturing facility in Wuhan Bio-Lake biotech industry development zone of China.
– The company provides outsourcing services for biopharmaceutical development and manufacturing.

Asia Biotechnology
Crunchbase icon

Content report

The following text will be sent to our editors: